1/30
09:07 am
kzia
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) [Yahoo! Finance]
Medium
Report
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) [Yahoo! Finance]
1/30
08:00 am
kzia
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Medium
Report
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
1/28
08:41 am
kzia
Novogen (NASDAQ:KZIA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Medium
Report
Novogen (NASDAQ:KZIA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
1/27
08:00 am
kzia
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
High
Report
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
1/24
05:09 am
kzia
Novogen (NASDAQ:KZIA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Novogen (NASDAQ:KZIA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/8
09:00 am
kzia
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
Low
Report
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
12/22
08:10 am
kzia
Kazia Therapeutics Regains Full Nasdaq Listing Compliance [Yahoo! Finance]
Medium
Report
Kazia Therapeutics Regains Full Nasdaq Listing Compliance [Yahoo! Finance]
12/22
08:00 am
kzia
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Medium
Report
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
12/12
08:06 am
kzia
Novogen (NASDAQ:KZIA) had its price target raised by analysts at HC Wainwright from $13.00 to $18.00. They now have a "buy" rating on the stock.
High
Report
Novogen (NASDAQ:KZIA) had its price target raised by analysts at HC Wainwright from $13.00 to $18.00. They now have a "buy" rating on the stock.
12/10
08:00 am
kzia
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
High
Report
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
12/2
09:00 am
kzia
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
Medium
Report
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
11/18
04:56 pm
kzia
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy [Yahoo! Finance]
High
Report
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy [Yahoo! Finance]
11/18
04:15 pm
kzia
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
High
Report
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy